RCT on the Treatment of Menopausal Syndrome With Chinese Medicine

Sponsor
Chinese University of Hong Kong (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06074809
Collaborator
(none)
78
1
2
27
2.9

Study Details

Study Description

Brief Summary

This is a double-blinded, randomized, placebo-controlled clinical trial. Subjects will be randomly assigned to the treatment group (Modified Guizhi Fuling granules) or placebo group (Placebo granules) for 8 weeks. Outcomes will be measured at week 8 and week 12.

Condition or Disease Intervention/Treatment Phase
  • Drug: Modified Guizhi Fuling granules
  • Other: Placebo
Phase 2

Detailed Description

Menopausal syndrome is a series of symptoms caused by ovarian follicles degeneration that occurs before or after menopause. These symptoms include central nervous system-related disorders (such as hot flashes, insomnia, depression, anxiety, etc.); metabolic, weight, cardiovascular and musculoskeletal changes; urogenital and skin atrophy; and sexual dysfunction.

Some previous studies have investigated the possibilities of using traditional Chinese medicine (TCM) for the treatment of menopausal syndrome. However, due to the limitations of previous clinical research, more evidence is required to support the efficacy of TCM treatment. Therefore, we propose to conduct a randomized, double-blinded, placebo-controlled clinical trial here, with the hope of objectively assessing the efficacy and safety of using TCM to treat menopausal syndrome.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
78 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Clinical Trial on the Treatment of Menopausal Syndrome With Chinese Medicine Gui-zhi-fu-ling-wan With Variation and the Mechanism of Anti-inflammation and Body Surface Temperature Distribution
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Oct 31, 2025
Anticipated Study Completion Date :
Jan 31, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Traditional Chinese medicine treatment group

Chinese medicine will be administered to patients in this group.

Drug: Modified Guizhi Fuling granules
Modified Guizhi Fuling granules will be orally administered to patients in the TCM treatment group twice a day throughout the treatment period, which lasts for 8 weeks.
Other Names:
  • Chinese medicine
  • Placebo Comparator: Placebo group

    Placebo will be administered to patients in this group.

    Other: Placebo
    Placebo will be orally administered to patients in the placebo group twice a day throughout the treatment period, which lasts for 8 weeks.

    Outcome Measures

    Primary Outcome Measures

    1. Greene Climacteric Scale (Chinese version) [Week 8]

      Greene Climacteric Scale (GCS) is one of the most common scales used to assess menopause. It includes four aspects of symptoms: vasomotor, somatic, psychological, and sexual response. This scale consists of 21 symptoms that can be assessed by patients themselves. The scoring from 0 to 3 in each item, indicates 'Not at all', 'A little bit', 'Much', and 'Very much' respectively.

    Secondary Outcome Measures

    1. Short-Form Health Survey, SF-12v2 (Chinese version) [Week 8]

      The SF-12v2 is the brief version of SF-36, consisting of 12 questions related to our physical, mental health and functionality. It is used as a supportive tool to comprehensively assess the health status of the patient. Scores range from 0 to 100, with higher scores representing better self-reported health.

    2. Short-Form Health Survey, SF-12v2 (Chinese version) [Week 12]

      The SF-12v2 is the brief version of SF-36, consisting of 12 questions related to our physical, mental health and functionality. It is used as a supportive tool to comprehensively assess the health status of the patient. Scores range from 0 to 100, with higher scores representing better self-reported health.

    3. Temperature change of face, limbs and abdomen [Week 8]

      The peripheral temperature of the face, limbs and abdomen of the patients will be measured by a thermographic camera.

    4. Temperature change of face, limbs and abdomen [Week 12]

      The peripheral temperature of the face, limbs and abdomen of the patients will be measured by a thermographic camera.

    5. Level change of sex hormones [Week 8]

      Level change of Estradiol (E2) and Follicle-stimulating hormone (FSH) will be measured between baseline and week 8.

    6. Level change of sex hormones [Week 12]

      Level change of Estradiol (E2) and Follicle-stimulating hormone (FSH) will be measured between baseline and week 12.

    7. Level change of inflammatory markers [Week 8]

      Level change of the serum inflammatory factors: high-sensitivity C-reactive protein (hsCRP), Interleukin 6 (IL-6) , Interleukin 8 (IL-8) and Tumor necrosis factor-α (TNF-α) will be measured from baseline to week 8.

    8. Level change of inflammatory markers [Week 12]

      Level change of the serum inflammatory factors: high-sensitivity C-reactive protein (hsCRP), Interleukin 6 (IL-6) , Interleukin 8 (IL-8) and Tumor necrosis factor-α (TNF-α) will be measured from baseline to week 12.

    9. Greene Climacteric Scale (Chinese version) [Week 12]

      Greene Climacteric Scale (GCS) is one of the most common scales used to assess menopause. It includes four aspects of symptoms: vasomotor, somatic, psychological, and sexual response. This scale consists of 21 symptoms that can be assessed by patients themselves. The scoring from 0 to 3 in each item, indicates 'Not at all', 'A little bit', 'Much', and 'Very much' respectively.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 60 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Female subjects with age between 40 and 60 years old;

    • For those who have symptoms of primary menopause (irregular menstruation lasting for more than 6 months, or absence of menstrual periods for more than 3 months)

    • The score of the physical symptoms in Greene Climacteric Symptom Score (GCS) is 6 or above (average level);

    • Have moderate level (affecting certain level of daily activity) or severe (cannot carry out daily activity) hot flashes, defined as transient sensations of heat, sweating, flushing, anxiety and chills lasting for 1-5 minutes;

    • Diagnosed Deficiency of Kidney essence and static blood in Lower Jiao by Chinese medicine practitioner

    • Agreed to receive Chinese medication or placebo for 2 months upon randomization.

    Exclusion Criteria:
    • The menopausal syndrome caused by surgical operations or medications (such as chemotherapy, gonadotropin-releasing hormone agonists, etc.).

    • Have received estrogen treatment in the past 2 months;

    • Have received any medication for treating menopause in the past month, including herbs, non-prescribed drugs, supplements, or change of diet to consume more legumes;

    • Known serious emotional, mental or psychological disorders that may affect the study;

    • During pregnancy, pre-pregnancy period, or lactation period;

    • Known history of allergy to any traditional Chinese medicine;

    • Have received anticoagulant or antiplatelet drugs in the past month;

    • Known history of some certain serious medical disease, such as cardiovascular disease, liver or renal dysfunction, diabetes, cerebrovascular disease, blood disorders, with unstable conditions;

    • Chinese medicine pattern combined with damp phlegm or damp heat, or only deficiency of Yin blood or absence of static blood pattern.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 School of Chinese Medicine Shatin Hong Kong

    Sponsors and Collaborators

    • Chinese University of Hong Kong

    Investigators

    • Principal Investigator: Hongwei Zhang, PhD, School of Chinese Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Zhang Hongwei, School of Chinese Medicine, Chinese University of Hong Kong
    ClinicalTrials.gov Identifier:
    NCT06074809
    Other Study ID Numbers:
    • Menopause study
    First Posted:
    Oct 10, 2023
    Last Update Posted:
    Oct 10, 2023
    Last Verified:
    Oct 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Zhang Hongwei, School of Chinese Medicine, Chinese University of Hong Kong

    Study Results

    No Results Posted as of Oct 10, 2023